AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The firm focuses on the discovery, development, and commercialization of prescription medicines. The firm operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. The company has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The firm distributes its products in over 125 countries.
Follow-Up Questions
Qui est le CEO de AstraZeneca PLC ?
Mr. Pascal Soriot est le Chief Executive Officer de AstraZeneca PLC, il a rejoint l'entreprise depuis 2012.
Quelle est la performance du prix de l'action AZNCF ?
Le prix actuel de AZNCF est de $161.9, il a decreased de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de AstraZeneca PLC ?
AstraZeneca PLC appartient à l'industrie Pharmaceuticals et le secteur est Health Care
Quel est la capitalisation boursière de AstraZeneca PLC ?
La capitalisation boursière actuelle de AstraZeneca PLC est de $250.9B
Est-ce que AstraZeneca PLC est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 28 analystes ont établi des notations d'analystes pour AstraZeneca PLC, y compris 10 achat fort, 19 achat, 5 maintien, 0 vente et 10 vente forte
